Cancer Stem Cells Market Share, Size & Trends Analysis Report By MoA (Stem Cell based Cancer Therapy, Targeted CSCs), By Cancer Forms (Breast Cancer, Bladder Cancer), And Segment Forecasts, 2018 - 2025
This report can be delivered to the clients within 24 hours
The global cancer stem cells market size is expected to reach USD 1.6 billion by 2025, according to a new report by Grand View Research, Inc., expanding at a CAGR of 9.98% during the forecast period. Although stem cell-based cancer treatment is facing regulatory and ethical challenges, the market is growing worldwide. With increasing awareness about these cells, there is steady growth in the R&D for the development of effective and novel treatment methods based on stem cells.
Furthermore, continuous rise has been observed in the number of research studies on cancer stem cells (CSCs) being published. These studies have helped healthcare professionals gain insights into CSCs biology and their signaling pathways. This is expected to create tremendous growth prospects for the market.
Furthermore, improvements in experimental approaches, in particular, in vitro assay systems have enabled scientists to establish relationship between different cell types in a tumor and their microenvironment. This has led to development of a broad therapeutic portfolio for CSCs and their associated key pathways for restricting growth of the tumor and providing improved clinical outcome.
Further key findings from the report suggest:
The global cancer stem cells market size is expected to reach USD 1.6 billion by 2025, according to a new report by Grand View Research, Inc., expanding at a CAGR of 9.98% during the forecast period. Although stem cell-based cancer treatment is facing regulatory and ethical challenges, the market is growing worldwide. With increasing awareness about these cells, there is steady growth in the R&D for the development of effective and novel treatment methods based on stem cells.
Furthermore, continuous rise has been observed in the number of research studies on cancer stem cells (CSCs) being published. These studies have helped healthcare professionals gain insights into CSCs biology and their signaling pathways. This is expected to create tremendous growth prospects for the market.
Furthermore, improvements in experimental approaches, in particular, in vitro assay systems have enabled scientists to establish relationship between different cell types in a tumor and their microenvironment. This has led to development of a broad therapeutic portfolio for CSCs and their associated key pathways for restricting growth of the tumor and providing improved clinical outcome.
Further key findings from the report suggest:
- The anti-CSC therapeutics segment accounted for a significant share owing to increasing R&D activities for the development of novel therapeutics
- Anti-CSCs therapeutics/agents include agents that target key pathways, surface markers, immuno-evasion & tumor microenvironment, along with nanoparticle-based therapies. As key pathways play a major role in tumor regulation, pathway inhibitors captured the largest share owing to the presence of a broad portfolio of products under pipeline
- With rising prevalence of bladder cancer, the segment is expected to exhibit the highest CAGR of 10.47% during the forecast period
- North America held the largest share in 2016 owing to presence of a large number of facilities in the U.S. that offer stem cell services
- Asia Pacific is likely to emerge as the fastest growing regional market owing to increasing investments by various agencies to accelerate research activities in Asian countries
- Some of the prominent players in the market are Thermo Fisher Scientific, Inc.; AbbVie, Inc.; Merck KGaA; Bionomics; and Lonza.
CHAPTER 1 RESEARCH METHODOLOGY
1.1 Information procurement
1.2 Information or Data Analysis
1.3 Market Formulation & Validation
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Snapshot
CHAPTER 3 MARKET VARIABLES, TRENDS& SCOPE
3.1 Market Segmentation &Scope
3.1.1 Market driver analysis
3.1.1.1 Increasing stem cell-based clinical trials
3.1.1.2 Increasing funding stem cell research as well as cancer
3.1.1.3 Robust pipeline of anti-CSCs therapeutics
3.1.1.4 Rising new cases of cancer
3.1.2 Market restraint analysis
3.1.2.1 Clinical issues pertaining to development & implementation of stem cell therapy
3.1.2.1.1 Manufacturing issues
3.1.2.1.2 Genetic instability
3.1.2.1.3 Stem cell culture condition
3.1.2.1.4 Stem cell distribution after transplant
3.1.2.1.5 Immunological rejection
3.2 Penetration &Growth Prospect Mapping For Products For Targeting CSC, 2016
3.3 Cancer stem cell-Swot Analysis, By Factor (Political & Legal, Economic And Technological)
3.4 Industry Analysis - Porter’s
3.5 Global Cancer Stem Cell-based Therapeutics Clinical Pipeline By Company & Phase
3.5.1 Preclinical
3.5.2 Phase I
3.5.3 Phase I/II
3.5.4 Phase III
3.5.5 Phase IV
3.5.6 In approval stage
3.6 Stem Cell Research Policies & Regulation Around the World
3.6.1 U.S
3.6.2 Canada
3.6.3 Germany
3.6.4 U.K.
3.6.5 Spain
3.6.6 Japan
3.6.7 China
3.6.8 South Korea
3.6.9 Australia
CHAPTER 4 CANCER STEM CELLS MARKET: MODE OF ACTION ESTIMATES & TREND ANALYSIS
4.1 Global Cancer stem cells market: Mode of Action Movement Analysis
4.2 Targeted Cancerous Stem Cells (CSCs)
4.2.1 Global target CSCs market, 2014 - 2025 (USD Million)
4.2.2 Global target CSCs market, by anti-cancer stem cell therapeutics
4.2.2.1 Pathway inhibitors
4.2.2.1.1 Global pathway inhibitors market, 2014 - 2025 (USD Million)
4.2.2.1.2 Wnt signaling pathway
4.2.2.1.3 Hedgehog (HH) signaling pathway
4.2.2.1.4 Notch signaling pathway
4.2.2.1.5 Others
4.2.2.2 Surface marker-based
4.2.2.2.1 Global surface marker-based market, 2014 - 2025 (USD Million)
4.2.2.3 Immuno-evasion & targeting tumor microenvironment
4.2.2.3.1 Global immuno-evasion & targeting tumor microenvironment market, 2014 - 2025 (USD Million)
4.2.2.4 Nanoparticle-based therapies
4.2.2.4.1 Global nanoparticle-based therapies market, 2014 - 2025 (USD Million)
4.2.2.5 Others
4.2.2.5.1 Global others market, 2014 - 2025 (USD Million)
4.2.3 Global target CSCs market, by products
4.2.3.1 Cell culturing
4.2.3.1.1 Global cell culturing market, 2014 - 2025 (USD Million)
4.2.3.2 Cell separation
4.2.3.2.1 Global cell separation market, 2014 - 2025 (USD Million)
4.2.3.3 Cell analysis
4.2.3.3.1 Global cell analysis market, 2014 - 2025 (USD Million)
4.2.3.4 Molecular analysis
4.2.3.4.1 Global molecular analysis market, 2014 - 2025 (USD Million)
4.2.3.5 Others
4.2.3.5.1 Global others market, 2014 - 2025 (USD Million)
4.3 Stem Cell-based Cancer Therapy
4.3.1 Global Stem Cell-based Cancer Therapy market, 2014 - 2025 (USD Million)
4.3.2 Autologous stem cell transplant
4.3.2.1 Global autologous stem cell transplant market, 2014 - 2025 (USD Million)
4.3.3 Allogeneic stem cell transplant
4.3.3.1 Global allogeneic stem cell transplant market, 2014 - 2025 (USD Million)
CHAPTER 5 CANCER STEM CELLS MARKET: CANCER FORMS ESTIMATES & TREND ANALYSIS
5.1 Global Cancer stem cells market: Cancer Forms Movement Analysis
5.2 Breast Cancer
5.2.1 Global breast cancer market, 2014 - 2025 (USD Million)
5.3 Blood Cancer
5.3.1 Global blood cancer market, 2014 - 2025 (USD Million)
5.4 Lung Cancer
5.4.1 Global lung cancer market, 2014 - 2025 (USD Million)
5.5 Brain Cancer
5.5.1 Global brain cancer market, 2014 - 2025 (USD Million)
5.6 Colorectal Cancer
5.6.1 Global colorectal cancer market, 2014 - 2025 (USD Million)
5.7 Pancreas Cancer
5.7.1 Global pancreas cancer market, 2014 - 2025 (USD Million)
5.8 Bladder Cancer
5.8.1 Global bladder cancer market, 2014 - 2025 (USD Million)
5.9 Liver Cancer
5.9.1 Global liver cancer market, 2014 - 2025 (USD Million)
5.10 Others
5.10.1 Global others market, 2014 - 2025 (USD Million)
CHAPTER 6 CANCER STEM CELLS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS, BY MODE OF ACTION AND CANCER FORMS
6.1 Cancer stem cells market Share By Region, 2016 & 2025
6.2 North America
6.2.1 North America cancer stem cells market, 2014 - 2025 (USD Million)
6.2.2 U.S.
6.2.2.1 U.S. cancer stem cells market, 2014 - 2025 (USD Million)
6.2.3 Canada
6.2.3.1 Canada cancer stem cells market, 2014 - 2025 (USD Million)
6.3 Europe
6.3.1 Europe cancer stem cells market, 2014 - 2025 (USD Million)
6.3.2 Germany
6.3.2.1 Germany cancer stem cells market, 2014 - 2025 (USD Million)
6.3.3 U.K.
6.3.3.1 U.K. cancer stem cells market, 2014 - 2025 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific cancer stem cells market, 2014 - 2025 (USD Million)
6.4.2 Japan
6.4.2.1 Japan cancer stem cells market, 2014 - 2025 (USD Million)
6.4.3 China
6.4.3.1 China cancer stem cells market, 2014 - 2025 (USD Million)
6.5 Latin America
6.5.1 Latin America cancer stem cells market, 2014 - 2025 (USD Million)
6.5.2 Brazil
6.5.2.1 Brazil cancer stem cells market, 2014 - 2025 (USD Million)
6.6 Middle East & Africa (MEA)
6.6.1 Middle East & Africa cancer stem cells market, 2014 - 2025 (USD Million)
6.6.2 South Africa
6.6.2.1 South Africa cancer stem cells market, 2014 - 2025 (USD Million)
CHAPTER 7 COMPETITIVE LANDSCAPE
7.1 List Of Companies
7.2 Strategy Framework
7.3 Market Participation Categorization
7.4 Company Profiles
7.4.1 Thermo Fisher Scientific, Inc.
7.4.1.1 Company Overview
7.4.1.2 Financial Performance
7.4.1.3 Product Benchmarking
7.4.1.4 Strategic Initiatives
7.4.2 AbbVie, Inc.
7.4.2.1 Company Overview
7.4.2.2 Financial performance
7.4.2.3 Product Benchmarking
7.4.2.4 Strategic initiatives
7.4.3 Merck KGaA
7.4.3.1 Company overview
7.4.3.1.1 Sigma-Aldrich Co. LLC
7.4.3.2 Financial performance
7.4.3.3 Product Benchmarking
7.4.3.4 Strategic Initiatives
7.4.4 Bionomics
7.4.4.1 Company Overview
7.4.4.2 Financial Performance
7.4.4.3 Product Benchmarking
7.4.4.4 Strategic Initiatives
7.4.5 LONZA
7.4.5.1 Company overview
7.4.5.2 Financial performance
7.4.5.3 Product Benchmarking
7.4.5.4 Strategic Initiatives
7.4.6 Stemline Therapeutics, Inc
7.4.6.1 Company overview
7.4.6.2 Financial performance
7.4.6.3 Product Benchmarking
7.4.6.4 Strategic Initiatives
7.4.7 Miltenyi Biotec
7.4.7.1 Company Overview
7.4.7.2 Financial Performance
7.4.7.3 Product Benchmarking
7.4.7.4 Strategic Initiatives
7.4.8 PromoCell GmbH
7.4.8.1 Company Overview
7.4.8.2 Financial Performance
7.4.8.3 Product Benchmarking
7.4.8.4 Strategic Initiatives
7.4.9 MacroGenics, Inc.
7.4.9.1 Company Overview
7.4.9.2 Financial Performance
7.4.9.3 Product Benchmarking
7.4.9.4 Strategic Initiatives
7.4.10 ONCOMED PHARMACEUTICALS INC
7.4.10.1 Company Overview
7.4.10.2 Financial performance
7.4.10.3 Product Benchmarking
7.4.10.4 Strategic Initiatives
7.4.11 Irvine Scientific
7.4.11.1 Company Overview
7.4.11.2 Financial Performance
7.4.11.3 Product Benchmarking
7.4.11.4 Strategic Initiatives
7.4.12 STEMCELL Technologies Inc
7.4.12.1 Company Overview
7.4.12.2 Financial Performance
7.4.12.3 Product Benchmarking
7.4.12.4 Strategic Initiatives
7.4.13 Sino Biological Inc
7.4.13.1 Company Overview
7.4.13.2 Financial Performance
7.4.13.3 Product Benchmarking
7.4.13.4 Strategic Initiatives
7.4.14 BIOTIME, INC.
7.4.14.1 Company overview
7.4.14.1.1 Cell Cure Neurosciences LTD.
7.4.14.1.2 ESI BIO
7.4.14.2 Financial performance
7.4.14.3 Product Benchmarking
7.4.14.4 Strategic Initiatives
1.1 Information procurement
1.2 Information or Data Analysis
1.3 Market Formulation & Validation
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Snapshot
CHAPTER 3 MARKET VARIABLES, TRENDS& SCOPE
3.1 Market Segmentation &Scope
3.1.1 Market driver analysis
3.1.1.1 Increasing stem cell-based clinical trials
3.1.1.2 Increasing funding stem cell research as well as cancer
3.1.1.3 Robust pipeline of anti-CSCs therapeutics
3.1.1.4 Rising new cases of cancer
3.1.2 Market restraint analysis
3.1.2.1 Clinical issues pertaining to development & implementation of stem cell therapy
3.1.2.1.1 Manufacturing issues
3.1.2.1.2 Genetic instability
3.1.2.1.3 Stem cell culture condition
3.1.2.1.4 Stem cell distribution after transplant
3.1.2.1.5 Immunological rejection
3.2 Penetration &Growth Prospect Mapping For Products For Targeting CSC, 2016
3.3 Cancer stem cell-Swot Analysis, By Factor (Political & Legal, Economic And Technological)
3.4 Industry Analysis - Porter’s
3.5 Global Cancer Stem Cell-based Therapeutics Clinical Pipeline By Company & Phase
3.5.1 Preclinical
3.5.2 Phase I
3.5.3 Phase I/II
3.5.4 Phase III
3.5.5 Phase IV
3.5.6 In approval stage
3.6 Stem Cell Research Policies & Regulation Around the World
3.6.1 U.S
3.6.2 Canada
3.6.3 Germany
3.6.4 U.K.
3.6.5 Spain
3.6.6 Japan
3.6.7 China
3.6.8 South Korea
3.6.9 Australia
CHAPTER 4 CANCER STEM CELLS MARKET: MODE OF ACTION ESTIMATES & TREND ANALYSIS
4.1 Global Cancer stem cells market: Mode of Action Movement Analysis
4.2 Targeted Cancerous Stem Cells (CSCs)
4.2.1 Global target CSCs market, 2014 - 2025 (USD Million)
4.2.2 Global target CSCs market, by anti-cancer stem cell therapeutics
4.2.2.1 Pathway inhibitors
4.2.2.1.1 Global pathway inhibitors market, 2014 - 2025 (USD Million)
4.2.2.1.2 Wnt signaling pathway
4.2.2.1.3 Hedgehog (HH) signaling pathway
4.2.2.1.4 Notch signaling pathway
4.2.2.1.5 Others
4.2.2.2 Surface marker-based
4.2.2.2.1 Global surface marker-based market, 2014 - 2025 (USD Million)
4.2.2.3 Immuno-evasion & targeting tumor microenvironment
4.2.2.3.1 Global immuno-evasion & targeting tumor microenvironment market, 2014 - 2025 (USD Million)
4.2.2.4 Nanoparticle-based therapies
4.2.2.4.1 Global nanoparticle-based therapies market, 2014 - 2025 (USD Million)
4.2.2.5 Others
4.2.2.5.1 Global others market, 2014 - 2025 (USD Million)
4.2.3 Global target CSCs market, by products
4.2.3.1 Cell culturing
4.2.3.1.1 Global cell culturing market, 2014 - 2025 (USD Million)
4.2.3.2 Cell separation
4.2.3.2.1 Global cell separation market, 2014 - 2025 (USD Million)
4.2.3.3 Cell analysis
4.2.3.3.1 Global cell analysis market, 2014 - 2025 (USD Million)
4.2.3.4 Molecular analysis
4.2.3.4.1 Global molecular analysis market, 2014 - 2025 (USD Million)
4.2.3.5 Others
4.2.3.5.1 Global others market, 2014 - 2025 (USD Million)
4.3 Stem Cell-based Cancer Therapy
4.3.1 Global Stem Cell-based Cancer Therapy market, 2014 - 2025 (USD Million)
4.3.2 Autologous stem cell transplant
4.3.2.1 Global autologous stem cell transplant market, 2014 - 2025 (USD Million)
4.3.3 Allogeneic stem cell transplant
4.3.3.1 Global allogeneic stem cell transplant market, 2014 - 2025 (USD Million)
CHAPTER 5 CANCER STEM CELLS MARKET: CANCER FORMS ESTIMATES & TREND ANALYSIS
5.1 Global Cancer stem cells market: Cancer Forms Movement Analysis
5.2 Breast Cancer
5.2.1 Global breast cancer market, 2014 - 2025 (USD Million)
5.3 Blood Cancer
5.3.1 Global blood cancer market, 2014 - 2025 (USD Million)
5.4 Lung Cancer
5.4.1 Global lung cancer market, 2014 - 2025 (USD Million)
5.5 Brain Cancer
5.5.1 Global brain cancer market, 2014 - 2025 (USD Million)
5.6 Colorectal Cancer
5.6.1 Global colorectal cancer market, 2014 - 2025 (USD Million)
5.7 Pancreas Cancer
5.7.1 Global pancreas cancer market, 2014 - 2025 (USD Million)
5.8 Bladder Cancer
5.8.1 Global bladder cancer market, 2014 - 2025 (USD Million)
5.9 Liver Cancer
5.9.1 Global liver cancer market, 2014 - 2025 (USD Million)
5.10 Others
5.10.1 Global others market, 2014 - 2025 (USD Million)
CHAPTER 6 CANCER STEM CELLS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS, BY MODE OF ACTION AND CANCER FORMS
6.1 Cancer stem cells market Share By Region, 2016 & 2025
6.2 North America
6.2.1 North America cancer stem cells market, 2014 - 2025 (USD Million)
6.2.2 U.S.
6.2.2.1 U.S. cancer stem cells market, 2014 - 2025 (USD Million)
6.2.3 Canada
6.2.3.1 Canada cancer stem cells market, 2014 - 2025 (USD Million)
6.3 Europe
6.3.1 Europe cancer stem cells market, 2014 - 2025 (USD Million)
6.3.2 Germany
6.3.2.1 Germany cancer stem cells market, 2014 - 2025 (USD Million)
6.3.3 U.K.
6.3.3.1 U.K. cancer stem cells market, 2014 - 2025 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific cancer stem cells market, 2014 - 2025 (USD Million)
6.4.2 Japan
6.4.2.1 Japan cancer stem cells market, 2014 - 2025 (USD Million)
6.4.3 China
6.4.3.1 China cancer stem cells market, 2014 - 2025 (USD Million)
6.5 Latin America
6.5.1 Latin America cancer stem cells market, 2014 - 2025 (USD Million)
6.5.2 Brazil
6.5.2.1 Brazil cancer stem cells market, 2014 - 2025 (USD Million)
6.6 Middle East & Africa (MEA)
6.6.1 Middle East & Africa cancer stem cells market, 2014 - 2025 (USD Million)
6.6.2 South Africa
6.6.2.1 South Africa cancer stem cells market, 2014 - 2025 (USD Million)
CHAPTER 7 COMPETITIVE LANDSCAPE
7.1 List Of Companies
7.2 Strategy Framework
7.3 Market Participation Categorization
7.4 Company Profiles
7.4.1 Thermo Fisher Scientific, Inc.
7.4.1.1 Company Overview
7.4.1.2 Financial Performance
7.4.1.3 Product Benchmarking
7.4.1.4 Strategic Initiatives
7.4.2 AbbVie, Inc.
7.4.2.1 Company Overview
7.4.2.2 Financial performance
7.4.2.3 Product Benchmarking
7.4.2.4 Strategic initiatives
7.4.3 Merck KGaA
7.4.3.1 Company overview
7.4.3.1.1 Sigma-Aldrich Co. LLC
7.4.3.2 Financial performance
7.4.3.3 Product Benchmarking
7.4.3.4 Strategic Initiatives
7.4.4 Bionomics
7.4.4.1 Company Overview
7.4.4.2 Financial Performance
7.4.4.3 Product Benchmarking
7.4.4.4 Strategic Initiatives
7.4.5 LONZA
7.4.5.1 Company overview
7.4.5.2 Financial performance
7.4.5.3 Product Benchmarking
7.4.5.4 Strategic Initiatives
7.4.6 Stemline Therapeutics, Inc
7.4.6.1 Company overview
7.4.6.2 Financial performance
7.4.6.3 Product Benchmarking
7.4.6.4 Strategic Initiatives
7.4.7 Miltenyi Biotec
7.4.7.1 Company Overview
7.4.7.2 Financial Performance
7.4.7.3 Product Benchmarking
7.4.7.4 Strategic Initiatives
7.4.8 PromoCell GmbH
7.4.8.1 Company Overview
7.4.8.2 Financial Performance
7.4.8.3 Product Benchmarking
7.4.8.4 Strategic Initiatives
7.4.9 MacroGenics, Inc.
7.4.9.1 Company Overview
7.4.9.2 Financial Performance
7.4.9.3 Product Benchmarking
7.4.9.4 Strategic Initiatives
7.4.10 ONCOMED PHARMACEUTICALS INC
7.4.10.1 Company Overview
7.4.10.2 Financial performance
7.4.10.3 Product Benchmarking
7.4.10.4 Strategic Initiatives
7.4.11 Irvine Scientific
7.4.11.1 Company Overview
7.4.11.2 Financial Performance
7.4.11.3 Product Benchmarking
7.4.11.4 Strategic Initiatives
7.4.12 STEMCELL Technologies Inc
7.4.12.1 Company Overview
7.4.12.2 Financial Performance
7.4.12.3 Product Benchmarking
7.4.12.4 Strategic Initiatives
7.4.13 Sino Biological Inc
7.4.13.1 Company Overview
7.4.13.2 Financial Performance
7.4.13.3 Product Benchmarking
7.4.13.4 Strategic Initiatives
7.4.14 BIOTIME, INC.
7.4.14.1 Company overview
7.4.14.1.1 Cell Cure Neurosciences LTD.
7.4.14.1.2 ESI BIO
7.4.14.2 Financial performance
7.4.14.3 Product Benchmarking
7.4.14.4 Strategic Initiatives
LIST OF TABLES
Table 1 Characteristics of 1,052 registered stem cell clinical trials and 286 trials that published primary outcome data in 333 publications with respect to status, phase, graft type, cell type, country, & funding, May 2017
Table 2 NIH funding for cancer (in USD millions)
Table 3 Pipeline of pathway inhibitors, 2016
Table 4 Pipeline of pathway inhibitors, 2015
Table 5 Wnt pathway inhibitors in clinical trials
Table 6 Cancers associated with Hedgehog signaling
Table 7 Selected hedgehog inhibitors in clinical development, 2014
Table 8 Cell surface antigens present on cancer stem cells
Table 9 List of nanoparticles targeting CSC
Table 10 Normal lung stem cells and associated lung cancer
Table 11 Examples of experimental studies performed to study putative cancer stem cell markers in lung cancer
Table 12 Monoclonal antibodies and nanocarriers against human colon cancer stem cells
Table 13 Current studies utilizing stem cells in various capacities for bladder bioengineering or regeneration
Table 14 North America cancer stem cells market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 15 North America anti-cancer stem cell therapeutics market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 16 North America pathway inhibitors market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 17 North America products for targeting CSC market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 18 North America Stem Cell-based Cancer Therapy market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 19 North America cancer stem cells market estimates & forecasts, by cancer forms, 2014 - 2025 (USD Million)
Table 20 U.S. cancer stem cells market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 21 U.S. anti-cancer stem cell therapeutics market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 22 U.S. pathway inhibitors market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 23 U.S. Products for targeting CSC market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 24 U.S. Stem Cell-based Cancer Therapy market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 25 U.S. cancer stem cells market estimates & forecasts, by cancer forms, 2014 - 2025 (USD Million)
Table 26 Canada cancer stem cells market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 27 Canada anti-cancer stem cell therapeutics market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 28 Canada pathway inhibitors market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 29 Canada products for targeting CSC market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 30 Canada Stem Cell-based Cancer Therapy market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 31 Canada cancer stem cells market estimates & forecasts, by cancer forms, 2014 - 2025 (USD Million)
Table 32 Europe cancer stem cells market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 33 Europe anti-cancer stem cell therapeutics market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 34 Europe pathway inhibitors market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 35 Europe products for targeting CSC market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 36 Europe Stem Cell-based Cancer Therapy market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 37 Europe cancer stem cells market estimates & forecasts, by cancer forms, 2014 - 2025 (USD Million)
Table 38 Germany cancer stem cells market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 39 Germany anti-cancer stem cell therapeutics market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 40 Germany pathway inhibitors market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 41 Germany products for targeting CSC market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 42 Germany Stem Cell-based Cancer Therapy market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 43 Germany cancer stem cells market estimates & forecasts, by cancer forms, 2014 - 2025 (USD Million)
Table 44 U.K. cancer stem cells market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 45 U.K. anti-cancer stem cell therapeutics market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 46 U.K. pathway inhibitors market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 47 U.K. products for targeting CSC market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 48 U.K. Stem Cell-based Cancer Therapy market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 49 U.K. cancer stem cells market estimates & forecasts, by cancer forms, 2014 - 2025 (USD Million)
Table 50 Asia Pacific cancer stem cells market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 51 Asia Pacific anti-cancer stem cell therapeutics market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 52 Asia Pacific pathway inhibitors market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 53 Asia Pacific products for targeting CSC market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 54 Asia Pacific Stem Cell-based Cancer Therapy market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 55 Asia Pacific cancer stem cells market estimates & forecasts, by cancer forms, 2014 - 2025 (USD Million)
Table 56 Japan cancer stem cells market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 57 Japan anti-cancer stem cell therapeutics market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 58 Japan pathway inhibitors market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 59 Japan products for targeting CSC market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 60 Japan Stem Cell-based Cancer Therapy market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 61 Japan cancer stem cells market estimates & forecasts, by cancer forms, 2014 - 2025 (USD Million)
Table 62 Main monographs on stem cells published in China
Table 63 China cancer stem cells market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 64 China anti-cancer stem cell therapeutics market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 65 China pathway inhibitors market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 66 China products for targeting CSC market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 67 China Stem Cell-based Cancer Therapy market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 68 China cancer stem cells market estimates & forecasts, by cancer forms, 2014 - 2025 (USD Million)
Table 69 Latin America cancer stem cells market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 70 Latin America anti-cancer stem cell therapeutics market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 71 Latin America pathway inhibitors market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 72 Latin America products for targeting CSC market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 73 Latin America Stem Cell-based Cancer Therapy market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 74 Latin America cancer stem cells market estimates & forecasts, by cancer forms, 2014 - 2025 (USD Million)
Table 75 Brazil cancer stem cells market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 76 Brazil anti-cancer stem cell therapeutics market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 77 Brazil pathway inhibitors market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 78 Brazil Products for targeting CSC market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 79 Brazil Stem Cell-based Cancer Therapy market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 80 Brazil cancer stem cells market estimates & forecasts, by cancer forms, 2014 - 2025 (USD Million)
Table 81 MEA cancer stem cells market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 82 MEA anti-cancer stem cell therapeutics market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 83 MEA pathway inhibitors market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 84 MEA products for targeting CSC market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 85 MEA Stem Cell-based Cancer Therapy market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 86 MEA cancer stem cells market estimates & forecasts, by cancer forms, 2014 - 2025 (USD Million)
Table 87 South Africa cancer stem cells market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 88 South Africa anti-cancer stem cell therapeutics market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 89 South Africa pathway inhibitors market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 90 South Africa products for targeting CSC market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 91 South Africa Stem Cell-based Cancer Therapy market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 92 South Africa cancer stem cells market estimates & forecasts, by cancer forms, 2014 - 2025 (USD Million)
Table 1 Characteristics of 1,052 registered stem cell clinical trials and 286 trials that published primary outcome data in 333 publications with respect to status, phase, graft type, cell type, country, & funding, May 2017
Table 2 NIH funding for cancer (in USD millions)
Table 3 Pipeline of pathway inhibitors, 2016
Table 4 Pipeline of pathway inhibitors, 2015
Table 5 Wnt pathway inhibitors in clinical trials
Table 6 Cancers associated with Hedgehog signaling
Table 7 Selected hedgehog inhibitors in clinical development, 2014
Table 8 Cell surface antigens present on cancer stem cells
Table 9 List of nanoparticles targeting CSC
Table 10 Normal lung stem cells and associated lung cancer
Table 11 Examples of experimental studies performed to study putative cancer stem cell markers in lung cancer
Table 12 Monoclonal antibodies and nanocarriers against human colon cancer stem cells
Table 13 Current studies utilizing stem cells in various capacities for bladder bioengineering or regeneration
Table 14 North America cancer stem cells market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 15 North America anti-cancer stem cell therapeutics market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 16 North America pathway inhibitors market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 17 North America products for targeting CSC market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 18 North America Stem Cell-based Cancer Therapy market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 19 North America cancer stem cells market estimates & forecasts, by cancer forms, 2014 - 2025 (USD Million)
Table 20 U.S. cancer stem cells market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 21 U.S. anti-cancer stem cell therapeutics market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 22 U.S. pathway inhibitors market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 23 U.S. Products for targeting CSC market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 24 U.S. Stem Cell-based Cancer Therapy market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 25 U.S. cancer stem cells market estimates & forecasts, by cancer forms, 2014 - 2025 (USD Million)
Table 26 Canada cancer stem cells market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 27 Canada anti-cancer stem cell therapeutics market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 28 Canada pathway inhibitors market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 29 Canada products for targeting CSC market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 30 Canada Stem Cell-based Cancer Therapy market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 31 Canada cancer stem cells market estimates & forecasts, by cancer forms, 2014 - 2025 (USD Million)
Table 32 Europe cancer stem cells market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 33 Europe anti-cancer stem cell therapeutics market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 34 Europe pathway inhibitors market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 35 Europe products for targeting CSC market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 36 Europe Stem Cell-based Cancer Therapy market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 37 Europe cancer stem cells market estimates & forecasts, by cancer forms, 2014 - 2025 (USD Million)
Table 38 Germany cancer stem cells market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 39 Germany anti-cancer stem cell therapeutics market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 40 Germany pathway inhibitors market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 41 Germany products for targeting CSC market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 42 Germany Stem Cell-based Cancer Therapy market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 43 Germany cancer stem cells market estimates & forecasts, by cancer forms, 2014 - 2025 (USD Million)
Table 44 U.K. cancer stem cells market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 45 U.K. anti-cancer stem cell therapeutics market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 46 U.K. pathway inhibitors market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 47 U.K. products for targeting CSC market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 48 U.K. Stem Cell-based Cancer Therapy market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 49 U.K. cancer stem cells market estimates & forecasts, by cancer forms, 2014 - 2025 (USD Million)
Table 50 Asia Pacific cancer stem cells market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 51 Asia Pacific anti-cancer stem cell therapeutics market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 52 Asia Pacific pathway inhibitors market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 53 Asia Pacific products for targeting CSC market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 54 Asia Pacific Stem Cell-based Cancer Therapy market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 55 Asia Pacific cancer stem cells market estimates & forecasts, by cancer forms, 2014 - 2025 (USD Million)
Table 56 Japan cancer stem cells market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 57 Japan anti-cancer stem cell therapeutics market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 58 Japan pathway inhibitors market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 59 Japan products for targeting CSC market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 60 Japan Stem Cell-based Cancer Therapy market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 61 Japan cancer stem cells market estimates & forecasts, by cancer forms, 2014 - 2025 (USD Million)
Table 62 Main monographs on stem cells published in China
Table 63 China cancer stem cells market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 64 China anti-cancer stem cell therapeutics market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 65 China pathway inhibitors market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 66 China products for targeting CSC market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 67 China Stem Cell-based Cancer Therapy market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 68 China cancer stem cells market estimates & forecasts, by cancer forms, 2014 - 2025 (USD Million)
Table 69 Latin America cancer stem cells market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 70 Latin America anti-cancer stem cell therapeutics market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 71 Latin America pathway inhibitors market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 72 Latin America products for targeting CSC market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 73 Latin America Stem Cell-based Cancer Therapy market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 74 Latin America cancer stem cells market estimates & forecasts, by cancer forms, 2014 - 2025 (USD Million)
Table 75 Brazil cancer stem cells market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 76 Brazil anti-cancer stem cell therapeutics market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 77 Brazil pathway inhibitors market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 78 Brazil Products for targeting CSC market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 79 Brazil Stem Cell-based Cancer Therapy market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 80 Brazil cancer stem cells market estimates & forecasts, by cancer forms, 2014 - 2025 (USD Million)
Table 81 MEA cancer stem cells market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 82 MEA anti-cancer stem cell therapeutics market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 83 MEA pathway inhibitors market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 84 MEA products for targeting CSC market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 85 MEA Stem Cell-based Cancer Therapy market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 86 MEA cancer stem cells market estimates & forecasts, by cancer forms, 2014 - 2025 (USD Million)
Table 87 South Africa cancer stem cells market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 88 South Africa anti-cancer stem cell therapeutics market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 89 South Africa pathway inhibitors market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 90 South Africa products for targeting CSC market estimates & forecasts, by mode of action (target Cancer stem cells), 2014 - 2025 (USD Million)
Table 91 South Africa Stem Cell-based Cancer Therapy market estimates & forecasts, by mode of action, 2014 - 2025 (USD Million)
Table 92 South Africa cancer stem cells market estimates & forecasts, by cancer forms, 2014 - 2025 (USD Million)
LIST OF FIGURES
Fig. 1 Market research process
Fig. 2 Information Procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 Market summary
Fig. 8 Market trends & outlook
Fig. 9 Market segmentation & scope
Fig. 10 Market driver relevance analysis (Current & future impact)
Fig. 11 Total number of cell therapy clinical trials, academic versus industry
Fig. 12 NIH spending on stem cell research, by year (in USD billions)
Fig. 13 Estimated new cancer cases and related mortality in the U.S, 2015-2017
Fig. 14 Estimated new cancers, female, 2016
Fig. 15 Estimated new cancers, male, 2016
Fig. 16 Market restraint relevance analysis (Current & future impact)
Fig. 17 Penetration & growth prospect mapping for products for targeting CSC, 2016
Fig. 18 SWOT Analysis, By Factor (political & legal, economic and technological)
Fig. 19 Porter’s Five Forces Analysis
Fig. 20 Global cancer stem cells market: Mode of action outlook key takeaways
Fig. 21 Comparison of traits of normal stem cells and cancer stem cell biology
Fig. 22 Global cancer stem cells market: Mode of action movement analysis
Fig. 23 Growth in journal articles on cancer stem cells
Fig. 24 Global target CSCs market, 2014 - 2025 (USD Million)
Fig. 25 Global pathway inhibitors market, 2014 - 2025 (USD Million)
Fig. 26 Global WNT signaling pathway market, 2014 - 2025 (USD Million)
Fig. 27 Global hedgehog signaling pathway market, 2014 - 2025 (USD Million)
Fig. 28 Global notch signaling pathway market, 2014 - 2025 (USD Million)
Fig. 29 Global others market, 2014 - 2025 (USD Million)
Fig. 30 Global surface marker-based market, 2014 - 2025 (USD Million)
Fig. 31 Global immuno-evasion & targeting tumor microenvironment market, 2014 - 2025 (USD Million)
Fig. 32 Global nanoparticle-based therapies market, 2014 - 2025 (USD Million)
Fig. 33 Global others market, 2014 - 2025 (USD Million)
Fig. 34 Global cell market, 2014 - 2025 (USD Million)
Fig. 35 Global cell culturing separation market, 2014 - 2025 (USD Million)
Fig. 36 Global cell analysis market, 2014 - 2025 (USD Million)
Fig. 37 Global molecular analysis market, 2014 - 2025 (USD Million)
Fig. 38 Global others market, 2014 - 2025 (USD Million)
Fig. 39 Global Stem Cell-based Cancer Therapy market, 2014 - 2025 (USD Million)
Fig. 40 Global autologous stem cell transplant market, 2014 - 2025 (USD Million)
Fig. 41 Global allogeneic stem cell transplant market, 2014 - 2025 (USD Million)
Fig. 42 Global cancer stem cells market: Cancer forms outlook key takeaways
Fig. 43 Various methods to detect cancer stem cells in different cancer forms
Fig. 44 Global cancer stem cells market: Workflow movement analysis
Fig. 45 New cases of breast cancer in the U.S., 2014 - 2017
Fig. 46 Global breast cancer market, 2014 - 2025 (USD Million)
Fig. 47 Estimated new cases of blood cancer in the U.S., 2014 - 2017
Fig. 48 Global blood cancer market, 2014 - 2025 (USD Million)
Fig. 49 Global lung cancer market, 2014 - 2025 (USD Million)
Fig. 50 Global brain cancer market, 2014 - 2025 (USD Million)
Fig. 51 Estimated new cases of colorectal cancer in the U.S., 2014 - 2017
Fig. 52 Global colorectal cancer market, 2014 - 2025 (USD Million)
Fig. 53 Global pancreas cancer market, 2014 - 2025 (USD Million)
Fig. 54 Global bladder cancer market, 2014 - 2025 (USD Million)
Fig. 55 Global liver cancer market, 2014 - 2025 (USD Million)
Fig. 56 Global others cancer market, 2014 - 2025 (USD Million)
Fig. 57 Regional market place: Key takeaway
Fig. 58 Cancer stem cell regional outlook, 2016 & 2025
Fig. 59 North America cancer stem cells market, 2014 - 2025 (USD Million)
Fig. 60 U.S. cancer stem cells market, 2014 - 2025 (USD Million)
Fig. 61 Canada cancer stem cells market, 2014 - 2025 (USD Million)
Fig. 62 Europe cancer stem cells market, 2014 - 2025 (USD Million)
Fig. 63 Germany cancer stem cells market, 2014 - 2025 (USD Million)
Fig. 64 U.K. cancer stem cells market, 2014 - 2025 (USD Million)
Fig. 65 Asia Pacific cancer stem cells market, 2014 - 2025 (USD Million)
Fig. 66 Japan cancer stem cells market, 2014 - 2025 (USD Million)
Fig. 67 China cancer stem cells market, 2014 - 2025 (USD Million)
Fig. 68 Latin America cancer stem cells market, 2014 - 2025 (USD Million)
Fig. 69 Brazil cancer stem cells market, 2014 - 2025 (USD Million)
Fig. 70 Middle East & Africa cancer stem cells market, 2014 - 2025 (USD Million)
Fig. 71 South Africa cancer stem cells market, 2014 - 2025 (USD Million)
Fig. 72 List Of Companies
Fig. 73 List Of Companies
Fig. 74 List Of Companies
Fig. 75 Strategy framework
Fig. 76 Participant categorization
Fig. 1 Market research process
Fig. 2 Information Procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 Market summary
Fig. 8 Market trends & outlook
Fig. 9 Market segmentation & scope
Fig. 10 Market driver relevance analysis (Current & future impact)
Fig. 11 Total number of cell therapy clinical trials, academic versus industry
Fig. 12 NIH spending on stem cell research, by year (in USD billions)
Fig. 13 Estimated new cancer cases and related mortality in the U.S, 2015-2017
Fig. 14 Estimated new cancers, female, 2016
Fig. 15 Estimated new cancers, male, 2016
Fig. 16 Market restraint relevance analysis (Current & future impact)
Fig. 17 Penetration & growth prospect mapping for products for targeting CSC, 2016
Fig. 18 SWOT Analysis, By Factor (political & legal, economic and technological)
Fig. 19 Porter’s Five Forces Analysis
Fig. 20 Global cancer stem cells market: Mode of action outlook key takeaways
Fig. 21 Comparison of traits of normal stem cells and cancer stem cell biology
Fig. 22 Global cancer stem cells market: Mode of action movement analysis
Fig. 23 Growth in journal articles on cancer stem cells
Fig. 24 Global target CSCs market, 2014 - 2025 (USD Million)
Fig. 25 Global pathway inhibitors market, 2014 - 2025 (USD Million)
Fig. 26 Global WNT signaling pathway market, 2014 - 2025 (USD Million)
Fig. 27 Global hedgehog signaling pathway market, 2014 - 2025 (USD Million)
Fig. 28 Global notch signaling pathway market, 2014 - 2025 (USD Million)
Fig. 29 Global others market, 2014 - 2025 (USD Million)
Fig. 30 Global surface marker-based market, 2014 - 2025 (USD Million)
Fig. 31 Global immuno-evasion & targeting tumor microenvironment market, 2014 - 2025 (USD Million)
Fig. 32 Global nanoparticle-based therapies market, 2014 - 2025 (USD Million)
Fig. 33 Global others market, 2014 - 2025 (USD Million)
Fig. 34 Global cell market, 2014 - 2025 (USD Million)
Fig. 35 Global cell culturing separation market, 2014 - 2025 (USD Million)
Fig. 36 Global cell analysis market, 2014 - 2025 (USD Million)
Fig. 37 Global molecular analysis market, 2014 - 2025 (USD Million)
Fig. 38 Global others market, 2014 - 2025 (USD Million)
Fig. 39 Global Stem Cell-based Cancer Therapy market, 2014 - 2025 (USD Million)
Fig. 40 Global autologous stem cell transplant market, 2014 - 2025 (USD Million)
Fig. 41 Global allogeneic stem cell transplant market, 2014 - 2025 (USD Million)
Fig. 42 Global cancer stem cells market: Cancer forms outlook key takeaways
Fig. 43 Various methods to detect cancer stem cells in different cancer forms
Fig. 44 Global cancer stem cells market: Workflow movement analysis
Fig. 45 New cases of breast cancer in the U.S., 2014 - 2017
Fig. 46 Global breast cancer market, 2014 - 2025 (USD Million)
Fig. 47 Estimated new cases of blood cancer in the U.S., 2014 - 2017
Fig. 48 Global blood cancer market, 2014 - 2025 (USD Million)
Fig. 49 Global lung cancer market, 2014 - 2025 (USD Million)
Fig. 50 Global brain cancer market, 2014 - 2025 (USD Million)
Fig. 51 Estimated new cases of colorectal cancer in the U.S., 2014 - 2017
Fig. 52 Global colorectal cancer market, 2014 - 2025 (USD Million)
Fig. 53 Global pancreas cancer market, 2014 - 2025 (USD Million)
Fig. 54 Global bladder cancer market, 2014 - 2025 (USD Million)
Fig. 55 Global liver cancer market, 2014 - 2025 (USD Million)
Fig. 56 Global others cancer market, 2014 - 2025 (USD Million)
Fig. 57 Regional market place: Key takeaway
Fig. 58 Cancer stem cell regional outlook, 2016 & 2025
Fig. 59 North America cancer stem cells market, 2014 - 2025 (USD Million)
Fig. 60 U.S. cancer stem cells market, 2014 - 2025 (USD Million)
Fig. 61 Canada cancer stem cells market, 2014 - 2025 (USD Million)
Fig. 62 Europe cancer stem cells market, 2014 - 2025 (USD Million)
Fig. 63 Germany cancer stem cells market, 2014 - 2025 (USD Million)
Fig. 64 U.K. cancer stem cells market, 2014 - 2025 (USD Million)
Fig. 65 Asia Pacific cancer stem cells market, 2014 - 2025 (USD Million)
Fig. 66 Japan cancer stem cells market, 2014 - 2025 (USD Million)
Fig. 67 China cancer stem cells market, 2014 - 2025 (USD Million)
Fig. 68 Latin America cancer stem cells market, 2014 - 2025 (USD Million)
Fig. 69 Brazil cancer stem cells market, 2014 - 2025 (USD Million)
Fig. 70 Middle East & Africa cancer stem cells market, 2014 - 2025 (USD Million)
Fig. 71 South Africa cancer stem cells market, 2014 - 2025 (USD Million)
Fig. 72 List Of Companies
Fig. 73 List Of Companies
Fig. 74 List Of Companies
Fig. 75 Strategy framework
Fig. 76 Participant categorization
